Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:JNJ NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$254.29+4.2%$227.70$184.63▼$261.64$449.28B0.37.16 million shs6.54 million shsJNJJohnson & Johnson$249.70+1.1%$238.64$162.30▼$269.43$601.08B0.248.45 million shs11.08 million shsMRKMerck & Co., Inc.$127.67+3.3%$119.48$76.66▼$130.29$315.32B0.1911.02 million shs12.40 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.22%-3.47%+10.29%+16.85%+30.91%JNJJohnson & Johnson-2.42%-6.06%+4.87%+5.53%+59.32%MRKMerck & Co., Inc.+2.19%-2.02%+7.41%+7.05%+51.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$254.29+4.2%$227.70$184.63▼$261.64$449.28B0.37.16 million shs6.54 million shsJNJJohnson & Johnson$249.70+1.1%$238.64$162.30▼$269.43$601.08B0.248.45 million shs11.08 million shsMRKMerck & Co., Inc.$127.67+3.3%$119.48$76.66▼$130.29$315.32B0.1911.02 million shs12.40 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.22%-3.47%+10.29%+16.85%+30.91%JNJJohnson & Johnson-2.42%-6.06%+4.87%+5.53%+59.32%MRKMerck & Co., Inc.+2.19%-2.02%+7.41%+7.05%+51.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$267.675.26% UpsideJNJJohnson & Johnson 2.74Moderate Buy$265.306.25% UpsideMRKMerck & Co., Inc. 2.70Moderate Buy$133.944.91% UpsideCurrent Analyst Ratings BreakdownLatest MRK, JNJ, and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Buy$280.007/16/2026JNJJohnson & Johnson ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$305.007/16/2026JNJJohnson & Johnson Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$258.00 ➝ $265.007/16/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$261.007/16/2026JNJJohnson & Johnson The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$282.007/16/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$284.00 ➝ $294.007/16/2026JNJJohnson & Johnson Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$263.00 ➝ $272.007/15/2026JNJJohnson & Johnson Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$260.007/15/2026ABBVAbbVie CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$230.00 ➝ $260.007/13/2026ABBVAbbVie UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$230.00 ➝ $260.007/13/2026JNJJohnson & Johnson TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$250.00 ➝ $300.00(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.35$15.74 per share16.16($1.83) per share-138.96JNJJohnson & Johnson$94.19B6.38$13.89 per share17.98$33.85 per share7.38MRKMerck & Co., Inc.$65.01B4.85$12.08 per share10.57$21.22 per share6.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03125.2715.770.815.79%-576.45%13.39%7/31/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6528.8719.772.4221.83%32.60%13.29%N/AMRKMerck & Co., Inc.$18.25B$3.5535.9612.963.0313.59%27.55%10.73%8/4/2026 (Estimated)Latest MRK, JNJ, and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026MRKMerck & Co., Inc.$1.36N/AN/AN/A$16.39 billionN/A7/31/2026Q2 2026ABBVAbbVie$3.71N/AN/AN/A$16.78 billionN/A7/15/2026Q2 2026JNJJohnson & Johnson$2.84$2.90+$0.06$2.27$25.02 billion$25.31 billion4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.72%+6.80%340.89%53 YearsJNJJohnson & Johnson$5.362.15%+5.25%61.97%64 YearsMRKMerck & Co., Inc.$3.402.66%+5.75%95.77%14 YearsLatest MRK, JNJ, and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/15/2026JNJJohnson & Johnsonquarterly$1.342.17%8/25/20268/25/20269/8/20266/18/2026ABBVAbbViequarterly$1.732.83%7/15/20267/15/20268/14/20265/26/2026MRKMerck & Co., Inc.quarterly$0.852.96%6/15/20266/15/20267/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68JNJJohnson & Johnson0.461.030.77MRKMerck & Co., Inc.1.021.301.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%JNJJohnson & Johnson0.16%MRKMerck & Co., Inc.0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableMRK, JNJ, and ABBV HeadlinesRecent News About These CompaniesFDA approves first-of-its-kind cholesterol pill Lipfendra: What it will cost2 minutes ago | finance.yahoo.comFDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio3 hours ago | benzinga.comFDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind3 hours ago | nypost.comNMerck Snags A First-Of-Its-Kind Approval, And Shares JumpJuly 16 at 12:51 PM | finance.yahoo.comMerck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC SaysJuly 16 at 12:51 PM | finance.yahoo.comMerck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise TargetsJuly 16 at 12:51 PM | finance.yahoo.comMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with HypercholesterolemiaJuly 16 at 7:50 AM | finance.yahoo.comMerck Gets Approval for Powerful Cholesterol-Cutting PillJuly 16 at 7:50 AM | finance.yahoo.comMerck Gets Approval for Powerful Cholesterol-Cutting PillJuly 16 at 7:00 AM | barrons.comMerck's cholesterol pill gets US FDA approvalJuly 16 at 6:49 AM | reuters.comMerck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with HypercholesterolemiaJuly 16 at 6:45 AM | businesswire.comThe FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieveJuly 16 at 6:45 AM | wsj.comWealthfront Advisers LLC Has $37.44 Million Holdings in Merck & Co., Inc. $MRKJuly 16 at 6:31 AM | marketbeat.comNavigation Group LLC Invests $1.24 Million in Merck & Co., Inc. $MRKJuly 16 at 6:07 AM | marketbeat.comTwin Capital Management Inc. Has $4.80 Million Stock Holdings in Merck & Co., Inc. $MRKJuly 16 at 5:59 AM | marketbeat.comIllinois Municipal Retirement Fund Trims Stock Holdings in Merck & Co., Inc. $MRKJuly 16 at 5:51 AM | marketbeat.comBank of New York Mellon Corp Has $2.25 Billion Holdings in Merck & Co., Inc. $MRKJuly 16 at 3:11 AM | marketbeat.comMerck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer UseJuly 15 at 1:03 PM | finance.yahoo.comMerck posts late-stage trial win for frontline Keytruda in endometrial cancerJuly 15 at 1:03 PM | seekingalpha.comCan Dow Jones' Merck Nab $25 Billion With Its Smart Bomb For Cancer?July 15 at 1:03 PM | finance.yahoo.comKEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to ChemotherapyJuly 15 at 8:02 AM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026SK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityBy Thomas Hughes | July 15, 2026MRK, JNJ, and ABBV Company DescriptionsAbbVie NYSE:ABBV$254.29 +10.18 (+4.17%) Closing price 03:59 PM EasternExtended Trading$252.52 -1.77 (-0.70%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$249.70 +2.68 (+1.08%) Closing price 03:59 PM EasternExtended Trading$250.74 +1.04 (+0.41%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Merck & Co., Inc. NYSE:MRK$127.67 +4.06 (+3.28%) Closing price 04:00 PM EasternExtended Trading$127.77 +0.10 (+0.08%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
